Quadruple Immunotherapy for Neuroblastoma
Condition: Neuroblastoma Recurrent Interventions: Biological: Natural killer cell; Drug: Dinutuximab beta; Drug: Interleukin-2; Drug: Granulocyte-Macrophage Colony-Stimulating Factor; Drug: Spironolactone Sponsors: Hong Kong Children's Hospital; The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma
Condition: Neuroblastoma Intervention: Other: horse therapy Sponsor: University Hospital, Toulouse Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Quadruple Immunotherapy for Neuroblastoma
Condition: Neuroblastoma Recurrent Interventions: Biological: Natural killer cell; Drug: Dinutuximab beta; Drug: Interleukin-2; Drug: Granulocyte-Macrophage Colony-Stimulating Factor; Drug: Spironolactone Sponsors: Hong Kong Children's Hospital; The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma
Condition: Neuroblastoma Intervention: Other: horse therapy Sponsor: University Hospital, Toulouse Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Quadruple Immunotherapy for Neuroblastoma
Condition: Neuroblastoma Recurrent Interventions: Biological: Natural killer cell; Drug: Dinutuximab beta; Drug: Interleukin-2; Drug: Granulocyte-Macrophage Colony-Stimulating Factor; Drug: Spironolactone Sponsors: Hong Kong Children's Hospital; The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma
Condition: Neuroblastoma Intervention: Other: horse therapy Sponsor: University Hospital, Toulouse Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Quadruple Immunotherapy for Neuroblastoma
Condition: Neuroblastoma Recurrent Interventions: Biological: Natural killer cell; Drug: Dinutuximab beta; Drug: Interleukin-2; Drug: Granulocyte-Macrophage Colony-Stimulating Factor; Drug: Spironolactone Sponsors: Hong Kong Children's Hospital; The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma
Condition: Neuroblastoma Intervention: Other: horse therapy Sponsor: University Hospital, Toulouse Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Quadruple Immunotherapy for Neuroblastoma
Condition: Neuroblastoma Recurrent Interventions: Biological: Natural killer cell; Drug: Dinutuximab beta; Drug: Interleukin-2; Drug: Granulocyte-Macrophage Colony-Stimulating Factor; Drug: Spironolactone Sponsors: Hong Kong Children's Hospital; The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma
Condition: Neuroblastoma Intervention: Other: horse therapy Sponsor: University Hospital, Toulouse Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Conditions: Neuroblastoma; Solid Tumor Interventions: Drug: APG-115; Drug: APG-2575 Sponsors: Ascentage Pharma Group Inc.; Suzhou Yasheng Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2023 Category: Research Source Type: clinical trials
